A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults with Tourette Syndrome
Phase 2 – studying effectiveness and dosage
Conditions:
Tourette's syndrome in adults (≥18 and ≤65 years) in out-patient care
Sponsor: Neurothera Labs Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
[CCI], [CCI], [CCI], [CCI], [CCI], [CCI], [CCI], Number of adverse events (AEs), number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs leading to withdrawal at each visit., Absolute values of vital signs (blood pressure, heart rate) at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.
[CCI]
Description
[CCI], [CCI], [CCI], [CCI], [CCI], [CCI], [CCI], Number of adverse events (AEs), number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs leading to withdrawal at each visit., Absolute values of vital signs (blood pressure, heart rate) at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 56 participants
БГ